This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This new monoclonal antibody therapy is designed to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in neonates and infants born during or entering their first RSV season. Dr. Octavio Ramilo, Chair of the Department of Infectious Diseases at St. A New Era in Infant RSV Protection Dr. Dean Y.
Johnson & Johnson Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies. Johnson & Johnson Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies. Source link.
That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. Breathe in, exhale.
The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.
However, recent insights indicate that it also operates beyond the nucleus, orchestrating initial events at the cell surface that trigger the activation of T cells. Remarkably, these findings propose that the presence of a cytoplasmic version of RARα is indispensable for T cells to initiate their defence against diseases.
NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15. No vaccine-related serious adverse events (SAEs) were observed. About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development. The study is being conducted at U.S.
In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 Serious adverse events were numerically more frequent with placebo than REGN-COV2 treatment (0.8% There was a 1.08 REGN-COV2 was well tolerated in the trial. high dose, 1.6% low dose; 2.3%
Member States will be provided with regular delivery schedules, and capped rebates will apply in the event of any delayed doses. In clinical trials, Vaxzevria demonstrated 100% efficacy against severe disease and hospitalisation after two doses. To date, AstraZeneca and its partners have supplied more than 1.1
Incidence of very rare thromboembolic events was far lower than in people diagnosed with COVID-19 infection. 1 Follow-up time was not sufficient to report rates after two doses of Vaxzevria , though other studies have shown rates of rare blood clotting events to be lower after a second dose.
Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% 100) against moderate or severe disease. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.
2 Since then, the FDA has approved four more AAV-based gene therapies—Zolgensma, Hemgenix, Elevidys and Rocktavian—for treating various diseases. 2 Since then, the FDA has approved four more AAV-based gene therapies—Zolgensma, Hemgenix, Elevidys and Rocktavian—for treating various diseases. Signal Transduct Target Ther. 2024;9(1):78.
While speaking at a virtual event hosted by Oddo BHF, a financial service group, Bancel said the “nightmare scenario” that the vaccine will not work is now in the past. FRIDAY, Jan. 8, 2021 — Moderna CEO Stéphane Bancel said the company’s COVID-19 vaccine may prevent infection for years, CBS News reported Thursday.
No serious adverse events related to the vaccine candidates studied were reported. The majority of adverse events were mild and transient. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.
No serious adverse events related to the vaccine candidates studied were reported. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. .
CHENGDU, China , Feb. For more information, visit www.dynavax.com.
11, 2020 — More than 15 million Americans have been infected by the COVID-19 virus, and many may be questioning whether they need to receive one of the two coronavirus vaccines now on the verge of approval from U.S. Centers for Disease Control and Prevention. FRIDAY, Dec. regulators. Short answer: Yes.
In the initial 275 patients, rates of adverse events (AEs) were similar among groups. Have chronic kidney disease. Have immunosuppressive disease. cardiovascular disease, OR. chronic obstructive pulmonary disease/other chronic respiratory disease. sickle cell disease, OR. Have diabetes.
Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Data from the event-driven trial could support global authorization and approval, including in the U.S. GAITHERSBURG, Md., 09, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. and globally.”.
The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. In June 2020, the two companies built upon the existing agreement to pursue novel mRNA vaccines to broadly address current and future infectious diseases.
.
Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. AstraZeneca.
About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. and Roche will develop, manufacture and distribute it outside the U.S.
Moleculin recently announced that the FDA had allowed its request for Investigational New Drug (IND) status for Annamycin, allowing Moleculin to begin a Phase 1B /2 clinical trial in the US for patients with soft tissue sarcoma (STS) that has metastasized to the lungs after first-line therapy for their disease. .
15, 2020 — A single pick-up hockey game in Tampa Bay in June wound up becoming a COVID-19 superspreader event, with one player infecting as many as 15 other people on the ice, Florida public health officials report. Centers for Disease Control and Prevention. THURSDAY, Oct. The other two sick people were not tested for COVID.
” Dr. Richard Hatchett , Chief Executive Officer of CEPI, commented: “To end the acute phase of this pandemic, and to control the virus in the longer term, the world needs multiple safe and effective vaccines which can be deployed in a range of populations and countries. .
EMERYVILLE, Calif. and CHENGDU, China , Feb.
It is estimated that there are over 6,000 monogenic diseases, affecting over 350 million people worldwide; for these diseases, cell and gene therapy may provide hope for a cure. There are three primary vectors employed in gene therapy: adeno-associated virus (AAV), adenovirus, or lentivirus vectors.
Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that it is entering a collaboration with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome (IBS).
Pascal Soriot, Chief Executive Officer, said: “Today’s recommendation underscores the value of AstraZeneca’s COVID-19 vaccine which is not only effective and well-tolerated, but also easy to administer and, importantly, protects fully against severe disease and hospitalisations.
Pascal Soriot, Chief Executive Officer, said: “Today’s approval underscores the value of AstraZeneca’s COVID-19 vaccine, which is not only effective and well tolerated, but also easy to administer and, importantly, protects fully against severe disease and hospitalisations.
It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. The overall reported rates of serious adverse events were 0.7% in the vaccine group and 0.8%
The Quebec City-based vaccine developer said that an interim analysis from the phase 1 study also showed no severe adverse events, and generally mild-to-moderate and brief reactogenicity events. Based on the promising phase 1 data, the company plans to proceed with a phase 2/3 clinical trial. “We Martin Berman-Gorvine.
InspirMed is a newly established subsidiary of TLC specializing in the development of inhalable liposome formulation programs, such as TLC19 for the treatment of Coronavirus disease 2019 (COVID-19) as well as other programs for severe acute and chronic pulmonary diseases. Cautionary Note on Forward-Looking Statements. Source link.
and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S.
At TOLREMO, we have developed a proprietary modular phenotypic screening platform that leverages transcriptional reprogramming events associated with non-genetic resistance to deliver new chemical scaffolds and identify novel resistance regulators.
It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. Available at: [link] [Accessed August 2021] 6. Available at SSRN: [link] [Accessed July 2021] 7.
A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. For more than 170 years, we have worked to make a difference for all who rely on us.
Each of these mechanisms represents a distinct strategy to address the underlying genetic perturbations contributing to disease pathogenesis. In sickle cell disease, for instance, a missense mutation in the HBB gene , encoding the beta-globin subunit of hemoglobin, leads to the production of abnormal hemoglobin S.
BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer.
ASLAN believes ASLAN003 has the potential to bethe most potent oral inhibitor of DHODH currently in development for autoimmune disease, more than 30 times more potent at inhibiting the DHODH enzyme than teriflunomide.
In preclinical studies, ASLAN003 was shown to be efficacious in animal models of MS and other autoimmune diseases.
Based on these findings, the single dose of the Janssen COVID-19 vaccine candidate of 5×10 10 virus particles (vp) has been selected for further evaluation in the Phase 3 ENSEMBLE clinical trial. These statements are based on current expectations of future events. Source link.
The work is supported by the Centers for Disease Control and Prevention (CDC). The analyses compared specific health events among all COVID-19 mRNA-vaccinated people during the first 3 weeks after inoculation with health events among similar types of patients during the 3 to 6 weeks after mRNA vaccination. doi: 10.1001/jama.2021.15072.
That’s why we created the Research & Innovation (R&I) Conference over 5 years ago, now one of ELRIG’s renowned flagship events. 2. Connect and collaborate to propel your career As an in-person event created and attended by those who truly know the value of collaboration, R&I offers an unparalleled networking opportunity.
Bill Anderson, chief executive officer of Roche Pharmaceuticals, said: “We are excited about the potential for one medicine to serve both as a treatment for those infected as well as protection for people exposed to the virus. REGN -COV2 could be a critical line of defense against the Covid-19 pandemic.”.
Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Interim data in this event-driven trial are expected as soon as early first quarter 2021, although the timing depends on the overall COVID-19 rate in the region.
Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content